A VC firm with offices in California, Beijing, and Hong Kong manages over 100 portfolio companies in the US and China. The firm generally invests in the early stages, mostly in seed and Series A rounds. The firm focuses its investments in U.S. and China, but also considers companies based in Canada.

In the life sciences sector, the firm will consider medical technology, diagnostic, and healthcare IT companies. The firm is open to all types of medical technology in all types of indications, and will look at both 510k and PMA medical devices in development or clinical trials. Previously, the firm has also invested in the synthetic engineering space.

The firm is looking for early-stage companies with a highly innovative product. The management team of potential portfolio companies is expected to be committed to the company full-time and will have a track of strong, successful entrepreneurship. The firm does not require a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office has a healthcare focused investment arm based in New York. The firm is interested in global companies, but is currently more focused on the US, Canada, Europe, and Israel regions. The firm makes investments ranging from $5 – $80 million. The firm is open to both leading and co-investing. The firm prefers investing in companies that have demonstrated clinical data and is currently not limited in the number of investments they plan to make this year.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is agnostic to the types of therapeutics, devices, and diagnostics they look to invest in. The firm is most interested in highly differentiable products that address unmet medical needs.

The firm looks for experienced management teams and depending on the deal, may or may not seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture / life science investment arm of a life science and medical equipment manufacturer invests from an evergreen fund. The firm prefers to invest at company formation / seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record, but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with regulatory affairs, market access and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Palo Alto, CA is looking for early stage life science opportunities. The firm also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in a total of 13 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and healthcare IT, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office located in New York makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor.

The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit.

The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life sciences and healthcare venture capital firm founded in 2014 is looking for global investment opportunities. The firm’s LPs include a pharma company and a government-owned fund of funds. The firm is currently allocating out of its $35M fund and actively seeking investment opportunities. The firm will typically participate in Seed to Series B rounds with initial sizes of investment ranging from $0.5M to $2.5M, and will earmark $1-3M for follow-on investments. The firm invests globally.

The firm is looking for companies with groundbreaking science and technology, and invests broadly across therapeutics, medical devices, diagnostics, and healthcare IT. The firm’s strongest expertise lies in therapeutics and they have invested the most in this sector. The firm will consider any asset from pre-clinical to phase II. The firm is open to all indications but is more selective when reviewing companies in overcrowded indications such as oncology.

The firm seeks innovative, high growth potential companies led by strong management teams, particularly with strong scientific expertise. The firm prefers to lead or co-lead investment rounds, especially if they are participating in Seed to Series A. They are also open to co-investing alongside other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment group founded by several Chinese medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel, pre-A, Series A, and B rounds. The group seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success.

The group is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. .

The group heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at Guoqian so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com